Gothenburg-based Cereno Scientific has made a number of preparations for the coming initiation of the phase II trial with their candidate CS1 in the rare cardiovascular disease PAH. CEO Sten R Sörensen visited BioStock’s studio to tell us more about this, the collaboration with Abbott, the coming subscription of TO1 and the expanded pipeline. Watch the interview, in Swedish, in the link below.
Watch the interview with Cereno Scientific’s CEO Sten R Sörensen in the link below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.